Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12188/16821
Title: Doxycycline-rifampin versus doxycycline-rifampingentamicin in treatment of human brucellosis.
Authors: Bosilkovski, Mile 
Kirovska, Valerija
Grozdanovski, Krsto 
Vidinic, Ivan
Demiri, Ilir 
Labachevski, Nikola 
Issue Date: 2012
Publisher: SAGE Publications
Source: Mile B, Valerija K, Krsto G, Ivan V, Ilir D, Nikola L. Doxycycline-rifampin versus doxycycline-rifampingentamicin in treatment of human brucellosis. Trop Doct. 2012;42(1):13-7.
Journal: Tropical Doctor
Abstract: This prospective, non-randomized trial, compared the efficacy and tolerance of a doxycycline-rifampin regimen, administered for 45 days, versus doxycycline-rifampin given for 45 days plus gentamicin for the first 7-10 days, in the treatment of human brucellosis. Of 238 patients that were initially included in the study, 181 were finally evaluated. Ninety-four were treated with the doxycycline-rifampin and 87 with the doxycycline-rifampin-gentamicin regimens. In the doxycycline-rifampin group: relapses were noted in 13 (13.8%) patients; therapeutic failures in five (5.3%); and mild adverse effects in 28 (29.8%). In the doxycycline-rifampin-gentamicin group: four (4.6%) relapsed; and five (5.7%) therapeutic failures were registered. Mild adverse effects were registered in 29 (33.3%) patients. The doxycycline-rifampin-gentamicin regimen demonstrated a significantly lower relapse rate compared to the doxycycline-rifampin combination (P = 0.034). We conclude that adding gentamicin for the first 7-10 days to the standard oral doxycycline-rifampin regimen can decrease the rate of relapses.
URI: http://hdl.handle.net/20.500.12188/16821
Appears in Collections:Faculty of Medicine: Journal Articles

Show full item record

Page view(s)

11
checked on Sep 30, 2022

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.